Name of journal: *World Journal of Gastrointestinal Endoscopy*

ESPS Manuscript NO: 14866

Columns: REVIEW

**Recent advancement of therapeutic endoscopy in the esophageal benign disease**

Bechara R *et al.*Therapeutic endoscopy in benign esophageal disease

Robert Bechara, Haruhiro Inoue

**Robert Bechara, Haruhiro Inoue,** Digestive Diseases Center, Showa University Koto-Toyosu Hospital, Koto-ku, Tokyo 135-0061, Japan

**Author contributions:** Bechara R and Inoue H both contributed to the writing of this paper.

**Conflict-of-interest:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Robert Bechara, HonBSc, MD, FRCPC,** Digestive Diseases Center, Showa University Koto-Toyosu Hospital, 5-1-38 Toyosu, Koto-ku, Tokyo 135-0061, Japan. [bechara.robert@gmail.com](mailto:bechara.robert@gmail.com)

**Telephone:** +81-3-62046064

**Fax:** +81-3-62046998

**Received:** October 28, 2014

**Peer-review started:** November 2, 2014

**First decision:** December 26, 2014

**Revised:** January 13, 2015

**Accepted:** February 4, 2015

**Article in press:**

**Published online:**

**Abstract**

Over the past 30 years, the field of endoscopy has witnessed several advances. With the advent of endoscopic mucosal resection, removal of large mucosal lesions have become possible. Thereafter, endoscopic submucosal resection was refined, permitting en bloc removal of large superficial neoplasms. Such techniques have facilitated the development of antireflux mucosectomy, a promising novel treatment for gastroesophageal reflux. The introduction and use of over the scope clips has allowed for endoscopic closure of defects in the gastrointestinal tract, which were traditionally treated with surgical intervention. With the development of Per-oral endoscopic myotomy (POEM), the treatment of achalasia and spastic disorders of the esophagus have been revolutionized. From the submucosal tunnelling technique developed for POEM, Per oral endoscopic tumor resection of subepithelial tumors was made possible. Simultaneously, advances in biotechnology have expanded esophageal stenting capabilities with the introduction of fully covered metal and plastic stents, as well as biodegradable stents. Once deemed a primarily diagnostic tool, endoscopy has quickly transcended to a minimally invasive intervention and therapeutic tool. These techniques are reviewed with regards to their application to benign disease of the esophagus.

**Key words:** POEM; POET; ARMS; Per-oral endoscopic myotomy; Per-oral endoscopic tumor resection; Antireflux mucosectomy; submucosal tumors; Subepithelial tumors; OTSC; Stents; Gastroesophageal reflux disease

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Antireflux mucosectomy is an endoscopic antireflux procedure showing promising results in patients with refractory gastroesophageal reflux. Over the scope clips and esophageal stents permit safe endoscopic closure of esophagogastric defects, decreasing the requirement for surgical intervention. Per-oral endoscopic myotomy allows the precise performance of endoscopic myotomy for the treatment of spastic esophageal motility disorders with the efficacy of a surgical myotomy without the associated surgical morbidity. Per oral endoscopic tumor enables en bloc endoscopic removal of subepithelial tumors (SETs) and is both a diagnostic and therapeutic intervention for esophageal SETs. These techniques will expand the boundaries of therapeutic endoscopy, decrease the need for surgical intervention, and improve patient outcomes.

Bechara R, Inoue H. Recent advancement of therapeutic endoscopy in the esophageal benign disease. *World J Gastrointest Endosc* 2015; In press

**Endoscopic Anti-reflux Procedures and Anti-Reflux Mucosectomy**

***Background***

Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal problems with an estimated increasing prevalence of over 25% in North America[1,2]. Consequently, it is a source of significant morbidity as well as considerable healthcare costs. In the United states alone, an estimated 9.3 billion dollars was incurred in direct healthcare cost as a result of GERD[3].

The standard surgical treatment for GERD is the Nissen fundoplication, where the fundus is wrapped around the lower esophagus to reinforce the lower esophageal sphincter (LES). This produces excellent short-term results and is generally safe with a post-operative complication rate of approximately 2%[4]. A recent multicenter randomized study showed that there was no significant difference in symptom remissions at five years follow-up between oral esomeprazole therapy and laparoscopic Nissen fundoplication[5,6]. Studies with longer term follow up, have reported relapse rates of up to 50% at 12 years post-laparoscopic Nissen fundoplication[7,8]. Furthermore, reoperations in these patients have increased morbidity and relapse is still a possibility[9,10].

Recently, there has been great interest in pursuing endoscopic alternatives to laparoscopic antireflux surgery. There are three general categories of such procedures; endoscopic devices for gastric plication, injection/implantable substances at the gastroesophageal junction (GEJ) and ablative therapies.

Endoscopic suturing devices allow plication 1-2 cm below the GEJ with the goal of reinforcing the LES, mimicking laparoscopic anti-reflux surgery. Depending on the device used, total procedure times can vary from 30-60 min. However, due to safety, cost, and questionable long term efficacy, many of these devices are no longer available. One currently available device is EsophyX® (EndoGastric Solutions, Washington, United States) which is marketed to deliver transoral incisionless fundoplication (TIF). Due to the fact that long term efficacy data are not available, significant cost of the device, and the need to confirm safety and define optimal technique, it has not become widely used[11].

Injectable treatments where liquid chemical polymers are directly injected into the LES which results in bulking and reinforcement of the natural barrier to reflux. These demonstrated promising early results, but have been removed from the market due to safety concerns related to transmural injection resulting in mediastinits, pericarditis, and death[12-14].

Ablative therapy consists of thermal energy delivered to the GEJ, which results in tissue remodeling that provides reinforcement to the LES. Stretta® (Mederi Therapeutics Inc., Connecticut, United States) is a currently available device which delivers low radiofrequency energy. The Stretta device has been available in the United States since 2000 and has good safety data, contrary to many of the previously mentioned therapies. There is evidence that at least in the short and mid-term, both subjective and objective improvement in GERD have been noted. Long term efficacy has not consistently been shown with some series showing 60% of patients proceed to antireflux surgery while others have shown more durable response[15-19].

Many of the studies on endoscopic antireflux procedures are limited to small single-center case series that demonstrate good short term improvement in symptoms. However, the long term durable efficacy has not been shown, with the few randomized control studies failing to show improvement over sham control arms. Due to the lack of evidence for adequate symptom control, associated high-cost and some safety concerns these endoscopic antireflux procedures have failed to become widely used.

With the introduction of strip biopsy by Tada *et al*[20] in 1984, ESD by Hirao *et al*[21] 1988, and cap EMR by Inoue *et al*[22] in 1990, resection of superficial gastrointestinal neoplasia has been revolutionized. The safety and efficacy of EMR/ESD have been well reported and are now widely applied by endoscopists around the world[23-25]. A known complication of esophageal ESD/EMR, particularly when more than two-thirds circumferential, is stricture development[26-28]. The exact mechanism of stricture formation is not known, but from experimental models it has been shown to involve acute inflammation, angiogenesis and fibrous hyperplasia with replacement of the submucosa with dense collagen fibers, and ultimately, atrophy in the muscularis propria[29,30]. In 2003, Inoue *et al*[22] reported a case of circumferential EMR for a short segment Barretts with high-grade dysplasia (HGD) that was found on endoscopy performed for objectively confirmed (24 h pH study) reflux symptoms. A circumferential EMR was performed extending to include a 2 cm wide portion of the gastric cardia. It was hypothesized that this would improve the reflux symptoms by causing fibrosis at the gastric cardia resulting in reinforcement of the LES. As expected, excellent symptomatic and objective (normalization of 24-h pH monitoring) improvement resulted and the patient has remained off of PPI for over 10 years[31]. Then in 2014, Inoue *et al*[32] published a series of 10 patients that received the antireflux mucosectomy (ARMS) procedure for refractory GERD showing excellent results both subjectively and objectively[32].

***Indications***

The GERD patients that are considered for ARMS are those without a large sliding hiatus hernia who have had objectively confirmed PPI refractory GERD. The presence of Barrett’s esophagus does not preclude the performance of ARMS.

***Technique***

The ARMSs procedure can be performed with ESD or EMR and is generally as follows: Step 1: Marking of area for mucosectomy. Mucosal reduction is planned along lesser curve of gastric cardia in crescentic manner (Figure 1A). When retroflexed in the stomach, the length of preserved mucosa on the side of the greater curve is estimated at approximately twice the diameter of the endoscope (about 2 cm); Step 2: Submucosal injection. Both EMR and ESD can be used depending on the experience of the operator and the presence of mucosal lesions. Submucosal injection is made along the markings to ensure adequate lift to prevent deep injury or perforation; and Step 3: Mucosectomy. The mucosectomy is then be performed via EMR or ESD (Figure 1B).

***Safety***

In the first two cases in the series, circumferential ARMS was performed which resulted in stricture formation that was successfully treated with balloon dilation. Subsequently, all ARMS were performed in a hemi-circumferential or crescentic fashion which produced adequate fibrosis to alleviate GERD without requirement for balloon dilation due to stricture formation[32].

***Efficacy***

All patients had significant improvement in subjective and objective parameters of GERD. The DeMeester, heartburn and regurgitation scores all showed significant impressive improvement. In 24 h esophageal pH monitoring, the fraction of time at pH < 4 improved from 29.1% to 3.1%[32].

***Conclusion***

This series of ARMS showed excellent safety and efficacy, however, the sample size was small, owing to the low incidence of GERD in Japan. Larger randomized studies are needed with longer follow-up to confirm the findings. Unique aspects of ARMS as an endoscopic treatment for GERD are that the safety of EMR/ESD have already been established, and endoscopists are already familiar with these techniques, allowing ARMS to be performed by endoscopists with expertise in esophogastric EMR/ESD. In addition, there is no requirement for new, expensive specialized equipment. Thus, if future studies confirm the efficacy, ARMS may be the ideal treatment for GERD that has been sought after, as it meets the requirements for safety, efficacy and cost-effectiveness.

**Over the Scope Clips**

***Background***

The over the scope clips (OTSCs) were initially introduced for closure of perforations and for mechanical hemostasis of complicated arterial bleeds of the gastrointestinal tract. The OTSC consist of a nitinol alloy with a similar shape to a bear trap. The clip, is preloaded on a clear applicator hood which is mounted onto the scope tip. The deployment system is analogous to that of a variceal banding device with the string running through the working channel of the endoscope and is attached to a rotatable handle that is attached to the port of the working channel.

***Indications***

Specifically pertaining to the esophagus, the OTSC has successfully been used for refractory bleeds (non-variceal), closer of iatrogenic perforations, Boerhaave's syndrome, anastomotic leaks, tracheaesophageal fistula and securing fully covered SEMS[33-43].

***Technique***

After mounting of the OTSC, the target area is identified, suctioned into the hood and the clip is deployed bringing the tissue into apposition. Alternatively, one of the available graspers or anchor can be used, allowing for direct visualization of the tissue to be clipped prior to clip deployed and for improved apposition of defects. Once the clip is deployed a permanent closing force of 8-9 Newtons (N) is applied to the tissue without causing necrosis[43]. Depending on the indication, different teeth are available; rounded (type a) for atraumatic application, pointed (type t) and long pointed (type gc) for more tissue apposition (Figure 2). Some of the challenges with the OTSC device are that it limits sharp angulation which can make maneuverability in the esophagus more challenging and there is slight impairment of the endoscopic view due to the attached OTSC device.

***Safety***

Complications with the OTSC have been uniformly rare in all the published series, the majority reporting no or few complications[33-41,43-52]. However, isolated cases of esophageal perforation, inadvertent tongue piercing and intestinal obstruction (from accidental inclusion of opposing walls into the OTSC) have been reported[44,51,53].

***Efficacy***

The OTSC device has been shown to be safe and effective for refractory arterial GI bleeding and closure of iatrogenic perforations 20 mm and smaller[47,51]. The successful of closure of anastomotic leaks and fistulas in case series has been largely large favorable, but has varied widely between 38%-100% in published series, due to heterogeneity of cases, series size and operators[36-38,40-43,45,48-51,54,55]. However, two recent meta-analysis showed success rates of 80%-100% for both perforation and fistula closure, with failure usually associated with chronic fibrotic fistula[52,56]. Most recently the European Society of Gastrointestinal Endoscopy released its position statement on iatrogenic endoscopic perforations and endorsed the use of the OTSC device for closure of esophageal perforations[57].

***Conclusion***

Multiple studies have reported that the OTSC device has good clinical efficacy for closure of esophageal, perforations, fistula and anastomotic leaks with few complications. Depending on the expertise available and the endoscopists experience the OTSC device should be considered an early treatment option for esophageal, perforation, leaks and fistula.

**POEMS**

***Background***

Achalasia is an esophageal motor disorder resulting from inhibitory neuron dysfunction causing loss of peristalsis and impaired LES relaxation. This leads to impaired food bolus propulsion and stasis in the esophagus. Patients may experience dysphagia, regurgitation, chest pain, weight loss and heartburn[58-60]. The conventional standard treatments are laparoscopic Heller myotomy (LHM) and pneumatic dilation (PD). The first account of an endoscopic myotomy as treatment dates back to 1980 by Ortega *et al*[61] in Venezuela, where they described two 1cm long myotomies to a depth of 3 mm performed at the LES in 17 patients. In 1997, Pasricha *et al*[62] in the United States, described an experimental technique on a bovine model, where a mucosal incision was made five centimetres above the GEJ and a balloon was placed into the submucosal space to create a tunnel down GEJ, where a myotomy of the circular muscle was performed[62]. In 2010, Inoue *et al*[32] in Japan modified the endoscopic myotomy procedure such that it permitted safe and effective human application. Since the introduction of POEM, there has been an exponential increase in POEM studies and the procedure is now being performed worldwide.

***Indications***

Currently, there are no universal guidelines for the indication of POEM. In experienced hands, it may be safer than LHM or PD. It is the opinion of the authors of this review that with the reported efficacy and safety from our center, that POEM maybe considered first line treatment for achalasia. POEM has been safety performed in patient with previous PD, LHM, Botox injection, or even prior POEM. In our center, it has also been safely performed in patients with type 1 and type 2 sigmoid achalasia as well as octogenarians. Other motility disorders such as diffuse esophageal spasm (DES), nutcracker esophagus, Jack-hammer esophagus, and hypertensive LES have also been successfully and safely treated with POEM.

***Technique***

The first successful case of POEM in a human was performed September, 2008 by Haruhiro Inoue. Since then, it has been widely accepted and performed with many slight variations to the original technique. The procedure as performed at our center is as follows (Figure 3): Step 1: Submucosal Injection and Incision. After the area of mucosal incision is chosen, generally about (13 cm above the GEJ for standard myotomy) approximately 10 cc of saline with indigocarmine is injected into the submucosa and an incision is made with a triangle-tip knife (KD-640 L; Olympus). To avoid mucosal injury, the submucosal tunnel is dissected as close as possible to the circular muscular; Step 2: Creation of the submucosal tunnel. After enough space is created in the submucosa, mucosal entry is achieved and the tunnel is carefully extended keeping the anatomical plane down onto the gastric side for approximately 3 cm; Step 3: Endoscopic myotomy. The circular muscle fibers are then carefully dissected with the Triangle tip knife. When there is no abnormal contraction of the esophageal body or symptoms of chest pain, the standard myotomy is made for 8-10 cm including 2-3 cm onto the gastric cardia; and Step 4: Closure of Mucosal entry. After completion of the myotomy and good hemostasis is confirmed, prophylactic antibiotic is instilled into submucosal tunnel and the mucosal entry site is clipped closed.

The main technical limitation to the performance of POEM is the presence of severe submucosal fibrosis of the distal esophagus which limits the ability to safety perform the submucosal tunnel and can occur when patients have had severe esophagitis or multiple previous endoscopic treatments.

***Safety***

Complications include; symptomatic and asymptomatic capnomediastinum, capnoperitoneum, intraprocedural and delayed bleeding, mucosal laceration/ischemia and GERD. The vast majority of complications reported have been treated conservatively and there have been no mortalities reported or requirement for conversion to open surgical procedure[63-73]. The most robust data comes from the international POEM survey (iPOEMS) database, major complications occurred in 3.2% of 841 cases[74] which were treated conservatively without sequelae. In comparison, the large European trial comparing PD and LHM showed a 4% perforation rate for PD and a 12% rate of mucosal tear for LHM[75].

There is variability in reporting and classification of complications, partially accounting for the variability in reported complication rates (Table 1). A standardized, internationally agreed upon adverse event reporting system for POEM is required. However, it is important to note that all the reported complications have been treated successfully endoscopically, with needle decompression or conservatively without any significant sequelae.

***Efficacy***

POEM is now being performed globally with excellent clinical results, with patients showing improvement of mean Eckardt scores from 5.4-8.8 pre-POEM to 0.4-1.7 post-POEM[63-68,76-81]. In addition, many have decreases in LES pressure and barium column height[63-67,76-79,82]. Success rates, defined by a post-POEM Eckardt score ≤ 3, are summarized in Table 1. Multiple comparative studies have shown that POEM is at least as effective as LHM with shorter hospital stay and decreased post-procedure pain[76-78].

POEM has also been shown to be also effective in patients with previous LHM. Zhou *et al*[83] reported mean improvement Eckardt score of 9.2 to 1.3, and Onimaru *et al*[81] reported mean improvement in Eckardt score of 6.5 to 1.1. Patients who have failed Botox injections or PD have also seen comparable improvements post POEM[84].

***Expanded Indications for other spastic esophageal motility disorders***

Generally, other spastic disorders of the esophagus that have been treated with surgically myotomy require a longer myotomy necessitating thoracotomy. This is another advantage of POEM, where a long myotomy can be performed without increased invasiveness or complications. From the IPOEMS database, which includes 841 patients, the POEM procedure was performed in 25 DES patients, 106 Nutcracker patients, and 58 Hypertensive LES (HTLES) patients. Compared to achalasia, POEM was equally effective in Nutcracker esophagus and HTLES, but less effective for DES[74]. In the recent series by Sharata *et al*[73] which included 12 Nutcracker esophagus, 5 DES, and 8 HTLES patients, complete dysphagia relief was achieved in 70.8% of non-achalasia cases, while chest pain was relieved in 91.5%[73]. There are also two case reports demonstrating successful application of POEM for Jackhammer esophagus[86,87].

***Areas of controversy***

In our center, the majority of POEM cases were performed at 2 o’clock (anterior-lesser curve) or 5 o’clock (posterior-lesser curve) positions. In some cases, previous procedures such as LHM, POEM, or ESD (for esophageal lesion) had been performed, precluding safe submucosal tunnelling in the normal location. In these cases, 7 o’clock or 8 o’clock (greater curve) myotomies were performed. At present there are no studies to guide which site of standard myotomy is most optimal. This will hopefully be addressed with a large multicenter, randomized trial in the near future.

Circular muscle myotomy is normally performed in our center. Nevertheless, some centers prefer a full thickness myotomy. Li *et al*[88] compared full thickness myotomy with circular muscle myotomy and found no difference in either efficacy or adverse events. However, shorter operative times are observed with full thickness myotomy[88]. Until there is more evidence, we suggest an isolated circular myotomy to prevent potential damage to adjacent structures and the development of capnoperitoneum/capnomediastinum.

***Conclusion***

Over 2000 POEM procedures have been performed worldwide. Most of the of the studies show excellent efficacy with low rate of major complications, most of which have easily managed without sequelae. Recent evidence may suggest that there is indication for POEM for other spastic disorders of esophagus. Over time, POEM may become the standard of care for achalasia and arguably other spastic disorders of the esophagus in the coming years.

**Per-Oral Endoscopic Tumor resection**

***Background***

Subepithelial tumors (SETs) of the upper gastrointestinal tract are generally uncommon with an incidence of about 0.4%[89]. Gastric SETs have a 50% malignancy rate, in contrast, esophageal SETs are usually benign leiomyomas and only 1%-3% are GISTS[89-91]. Generally, SETs are asymptomatic and found incidentally on endoscopic or radiologic examination for unrelated symptoms or screening. However, larger SETs can cause dysphagia, chest pain, regurgitation and bleeding[92,93]. Traditionally, excision of symptomatic SETs has been performed with open surgical, laparoscopic or thoracoscopic techniques. These procedures are invasive, associated with significant health care cost and significant morbidity[94-96]. In addition, if the lesion in question is benign it may be difficult to justify excision with associated morbidity. With the introduction of POEM, the submucosal tunnelling technique has been subsequently applied for Per-oral endoscopic tumor (POET) resection by Inoue *et al*[97] in 2012. The technique has allowed SETs to be removed from the esophagus and gastric cardia, safety and effectively. Since its first description, multiple series have been published confirming its safety and efficacy.

***Indications***

Most of the SETs removed *via* POET resection have been benign. The presumptive diagnoses were made using a combination of endoscopy, endoscopic ultrasound (EUS) and CT scan. Indications for resection were presence of symptoms, enlarging tumor or unclear diagnosis in which resection was diagnostic.

***Technique***

An essential part of the POET (and POEM) procedure is use of low flow carbon dioxide insufflation to prevent complication from barotrauama as noted by Wang *et al*[98], where air insufflation was used in the first half of their series, which resulted in high rates subcutaneous emphysema, pneumothorax and pneumomediastinum. Thus, they used carbon dioxide insufflation for the remaining cases and subsequently did not have further adverse events related to insufflation[98]. The POET technique can be summarized as follows with the various steps shown in Figure 4: Step 1: Submucosal Injection and Incision. The area of mucosal incision is generally 5 cm proximal to the tumor and is made as described for POEM; Step 2: Creation of the submucosal tunnel. The submucosal tunnel is extended 1-2 cm distal to the tumor to ensure sufficient working space for the dissection of the tumour; Step 3: Tumour Resection. Once the mass is identified and the tunnel is sufficient, resection of the tumor can proceed. Careful dissection of the mass from the muscular layer should be performed to prevent rupture of capsule or perforation of the overlying mucosa. Tumors that extend to the deep muscular layer can be removed with a full thickness resection. The free tumor can be withdrawn through the mucosal incision using a snare, grasping forceps or suctioning into the cap; and Step 4: Closure of Mucosal entry. The tunnel is re-examined to confirm adequate hemostasis and the mucosal incision is closed with endoscopic clips. There are also reports of using endoscopic staples, OTSCs, as well as covered metal stents to seal the mucosal incision site[99-102].

Patients are managed analogous to POEM for achalasia. Patients are kept nil per os (NPO) for 24 h. Day 1 post procedure the patient has an endoscopy as well as a contrast study to check for leak. Some centers perform routine post-procedure CT scan to check for insufflation related complications and perforation[103]. The patient’s diet is advanced to clear liquids day-1 post-procedure, and a regular diet day-2 post-procedure if asymptomatic. Endoscopy and endoscopic ultrasound are generally performed for follow-up on patients that underwent POET resection. If the lesion removed is malignant or with potential, closer follow-up is performed and includes a CT scan to assess tumor recurrence around the area of resection and distance metastasis[98,104].

***Safety***

Almost all of the reported complications have been insufflation related (subcutaneous emphysema, pneumoperitoneum and pneumomediastinum). All were managed with decompression or conservatively without sequelae. Again, analogous to POEM series, there is variability in reporting and classification of complications.

***Efficacy***

Nearly all series report 100% successful resection (refer to Table 2). With almost all being en bloc with intact capsule. A complete resection is an en bloc resection of the tumor with intact capsule. This factor is very important especially if there is a pre-procedure diagnosis is suggestive of a malignant or pre-malignant lesion in order to prevent seeding. The limiting factor for resection of SETs *via* POET is size. The largest SET removed to date was 60 mm × 28 mm × 22 mm[100]. The tumor (known to be leiomyoma) required fragmentation to be extracted, even after extension of the mucosal incision. In addition, the mucosal incision could not be closed and necessitated placement of fully covered SEMS. Anecdotally, it appears that the upper limit for a complete resection is 4-5cm depending if the shape of the tumor allows for extraction through the mucosal incision site. The efficacy data is summarized in Table 2 below.

***Conclusion***

Subepithelial tumors of the esophagus and cardia are usually incidental findings on endoscopic or radiologic examinations for unrelated symptoms, with the majority being reported as benign. With the moderate yield of EUS, morbidity, healthcare costs and even mortality of surgical resection, a minimally invasive diagnostic and therapeutic procedure is needed for the management of SETs. The careful performance of POET is very efficacious, generally safe and with continued supportive evidence will likely replace surgical resection of most esophageal and gastric cardia SETs, with surgical resection reserved for very large SETs.

**Stents**

***Background***

When first introduced in 1959, esophageal stents were placed intra-operatively and were indicated only for palliation of dysphagia for non-operable malignant strictures[112]. Endoscopic stents were subsequently introduced in 1977, but were plagued with high complication rates[113]. Since then, self-expandable metal stents (SEMs) have become widely used for palliation of dysphagia for non-operable malignant esophageal strictures with good safety, efficacy, and cost effectiveness data[114,115]. With the success of SEMs for malignant esophageal disease, there was an effort to expand the use of uncovered/partially covered SEMSs for the use of benign esophageal disease. However, it was found early on that these SEMSs resulted in increased complications when used for benign disease. Such complications included migration, tissue ingrowth, stent induced stenosis, development of tracheoesogeal fistula, and hemorrhage[116-118].

With the hope to ameliorate the serious issues that the SEMS caused when used for benign disease, manufacturers have introduced the fully covered self-expandable metal stents (FCSEMS), self-expandable plastic stents (SEPS) and biodegradable stents (BDS).

***Indications***

For patients with iatrogenic perforations, tracheoesophgeal fistula, and/or surgical interventions complicated by anastomotic leaks, the treatment has traditionally been surgical intervention. However, with the advent of FCSEMS and SEPS, these have been increasingly used as means to prevent reoperation and to allow healing to take place. Another emerging use is for refractory benign esophageal strictures in which traditional management with dilation has failed.

***Equipment***

There are currently a variety of stents available depending on the country. Below is a brief summary (Table 3) of the general differences between the FCSEMS, SEPS and BDS with focus on benign esophageal strictures. Examples of each group are shown in Figure 5.

***Technique***

Once the stricture has been deemed refractory and stenting is considered, or a defect requires closure, then the choice of stent depends on the position and length of stricture/defect and preference of the endoscopist. The length of the stent should be at least about 3-4 cm longer the stricture/defect. The endoscopist should carefully assess the stricture/perforation/fistula noting the proximal and distal margins, the distance from the upper and LESs and ensure that the defect/stricture is greater than 2 cm away from the upper esophageal sphincter, as if this distance is less it may preclude safe stent placement. If the stent is to be deployed across the LES, then a stent with an antireflux valve can be considered if available. Once the location of stent placement is chosen, the proximal and distal margins can be marked endoscopically (submucosal injection of radiopaque substance or placement of clips), by specific anatomic landmarks under X-ray or placement of radiopaque markers on the patient. If simultaneous endoscopic visualization is desired, an ultra slim scope can be used transnasally. Under fluoroscopic control, the stent is deployed with keeping adequate margins on both sides. Endoscopic clips, OTSCs or an endoscopic suturing device can used to decrease the risk of stent migration[34,119-122]. After deployment, the stents will radially expand and shorten reaching its final form.

***Efficacy***

Efficacy is defined as technical and clinical success. Technical success is defined as successful deployment of the stent where clinical success is the achievement of the intended clinical outcome (improvement in dysphagia, closure and healing of defect). FCSEMS and SEPS show excellent technical and good clinical efficacy for the closure of benign gastrointestinal disruptions with a technical success of 91% and clinical success (closure rate) of 81%[123]. In the cases where only partial closure achieved, surgical reinvention is still often avoided[123].

Unfortunately, for benign strictures, the clinical efficacy of FCSEMS and SEPS is less promising than for benign disruptions with a range of clinical success rate of only 40%-50%[124,125]. Biodegradable stents were introduced with the hopes of improving the shortcomings of the modest clinical efficacy of FCSEMS and SEPS. Unfortunately, the clinical efficacy of BDS has not differed significantly compared to its predecessors, with mean clinical success rate of 47%[126]. However, in the pediatric population, with the use of custom made plastic stents higher efficacy rates have been demonstrated. Also, with the stents fastened to a nasogastric tube with an external silicon bar at the naris to avoid distal migration, much lower migration rates have been observed[127,128].

***Safety***

FCSEMS and SEPS have a modest complication rate, with the most common being stent migration at about 25%-30% with and with some evidence that the risk of migration is higher with SEPS[129,130]. The risk of migration may also be higher for proximal and anastomotic strictures[131]. Other less common, not uniformly reported complications include perforation, tissue hyperplasia, stent induced strictures, hemorrhage, and post-procedure pain. A rare but dreaded complication is the development of an aortoenteric fistula, which is usually fatal[132-134]. BDS have a lower risk of migration of about 20% and fewer complications overall, but may have increased post-procedure pain[126,135,136].

***Conclusion***

There is mounting evidence for the efficacy of FCSEMS and SEPS for closure benign gastrointestinal disruptions with a moderate risk of migration. For refractory strictures, the efficacy is less promising likely owing to varying endoscopy skillsets, heterogeneity of patients and extreme severity of stricture pathology being treated. Depending on the individual case and the experience of the endoscopist, FCSEMS, SEPS, and BDS are potential options for select patients with refractory strictures. The particular choice of stent depends on the perceived risk or migration, tissue hyperplasia and other complications, as well as the endoscopist preference and experience. Hopefully with improvement in stent design, refinement in technique and patient selection, there will be improved clinical efficacy and safety for stenting of benign esophageal strictures.

**Summary**

Endoscopy has drastically advanced from being primarily as a diagnostic procedure to becoming the preferred modality in the treatment of benign disease of the esophagus. Promising efficacy and safety data of POEM and POET is accumulating, and with careful application, these procedures may soon be heralded as the standard of care for various diseases. Despite being a novel procedure, there is extensive experience with ARMS in the setting of EMR/ESD with established safety data, and provides patients with another endoscopic procedure that may replace traditional surgical intervention for the treatment of GERD if efficacy is reported by large trials. OTSC usage is becoming widespread and has a remarkably low complication rate with good efficacy in facilitating the closure of esophageal perforations, fistula, and leaks. Thus, the OTSCs can be considered a first line treatment in selected patients. At present, the evidence for treatment of benign esophageal disruptions is promising and FCSEMS and SEPS should be considered in their treatment. However, for benign esophageal strictures the evidence for the use of FCSEMS, SEPS and BDS has been conflicting, but with further refinement of technique, application, and/or technology used, there is potential for more consistent favorable patient outcomes.

With the ongoing introduction of novel procedures and equipment, it is critical that patient safety remain the top priority. International collaboration in the form of large multi-centered studies will provide the opportunity to adequately study safety and therapeutic efficacy of newly introduced equipment and techniques.

**References**

1 **El-Serag HB**. Time trends of gastroesophageal reflux disease: a systematic review. *Clin Gastroenterol Hepatol* 2007; **5**: 17-26 [PMID: 17142109 DOI: 10.1016/j.cgh.2006.09.016]

2 **El-Serag HB**, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut* 2014; **63**: 871-880 [PMID: 23853213 DOI: 10.1136/gutjnl-2012-304269]

3 **Sandler RS**, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. *Gastroenterology* 2002; **122**: 1500-1511 [PMID: 11984534 DOI: 10.1053/gast.2002.32978]

4 **Telem DA**, Altieri M, Gracia G, Pryor AD. Perioperative outcome of esophageal fundoplication for gastroesophageal reflux disease in obese and morbidly obese patients. *Am J Surg* 2014; **208**: 163-168 [PMID: 24881017 DOI: 10.1016/j.amjsurg.2014.02.010]

5 **Attwood SE**, Lundell L, Ell C, Galmiche JP, Hatlebakk J, Fiocca R, Lind T, Eklund S, Junghard O. Standardization of surgical technique in antireflux surgery: the LOTUS Trial experience. *World J Surg* 2008; **32**: 995-998 [PMID: 18224465 DOI: 10.1007/s00268-007-9409-4]

6 **Galmiche JP**, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, Långström G, Lind T, Lundell L. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. *JAMA* 2011; **305**: 1969-1977 [PMID: 21586712 DOI: 10.1001/jama.2011.626]

7 **Kellokumpu I**, Voutilainen M, Haglund C, Färkkilä M, Roberts PJ, Kautiainen H. Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes. *World J Gastroenterol* 2013; **19**: 3810-3818 [PMID: 23840119 DOI: 10.3748/wjg.v19.i24.3810]

8 **Lundell L**, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Engström C, Julkunen R, Montgomery M, Malm A, Lind T, Walan A. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. *Clin Gastroenterol Hepatol* 2009; **7**: 1292-128; quiz 1260 [PMID: 19490952 DOI: 10.1016/j.cgh.2009.05.021]

9 **Makdisi G**, Nichols FC, Cassivi SD, Wigle DA, Shen KR, Allen MS, Deschamps C. Laparoscopic repair for failed antireflux procedures. *Ann Thorac Surg* 2014; **98**: 1261-1266 [PMID: 25129552 DOI: 10.1016/j.athoracsur.2014.05.036]

10 **Wakeam E**, Wee J, Lebenthal A, Ali SO, Gilbert RJ, Bueno R. Does BMI predict recurrence or complications after reoperative reflux surgery? Review of a single center's experience and a comparison of outcomes. *J Gastrointest Surg* 2014; **18**: 1965-1973 [PMID: 25227639 DOI: 10.1007/s11605-014-2656-4]

11 **Auyang ED**, Carter P, Rauth T, Fanelli RD. SAGES clinical spotlight review: endoluminal treatments for gastroesophageal reflux disease (GERD). *Surg Endosc* 2013; **27**: 2658-2672 [PMID: 23801538 DOI: 10.1007/s00464-013-3010-8]

12 **Wong RF**, Davis TV, Peterson KA. Complications involving the mediastinum after injection of Enteryx for GERD. *Gastrointest Endosc* 2005; **61**: 753-756 [PMID: 15855987 DOI: 10.1016/S0016-5107(04)02645-8]

13 **Cicala M**, Gabbrielli A, Emerenziani S, Guarino MP, Ribolsi M, Caviglia R, Costamagna G. Effect of endoscopic augmentation of the lower oesophageal sphincter (Gatekeeper reflux repair system) on intraoesophageal dynamic characteristics of acid reflux. *Gut* 2005; **54**: 183-186 [PMID: 15647177 DOI: 10.1136/gut.2004.040501]

14 **Alzahrani A**, Anvari M, Dallemagne B, Mutter D, Marescaux J. Surgical approach after failed enteryx injection for GERD. *JSLS* 2007; **11**: 97-100 [PMID: 17651566]

15 **Perry KA**, Banerjee A, Melvin WS. Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. *Surg Laparosc Endosc Percutan Tech* 2012; **22**: 283-288 [PMID: 22874675 DOI: 10.1097/SLE.0b013e3182582e92]

16 **Dundon JM**, Davis SS, Hazey JW, Narula V, Muscarella P, Melvin WS. Radiofrequency energy delivery to the lower esophageal sphincter (Stretta procedure) does not provide long-term symptom control. *Surg Innov* 2008; **15**: 297-301 [PMID: 18829607 DOI: 10.1177/1553350608324508]

17 **Aziz AM**, El-Khayat HR, Sadek A, Mattar SG, McNulty G, Kongkam P, Guda MF, Lehman GA. A prospective randomized trial of sham, single-dose Stretta, and double-dose Stretta for the treatment of gastroesophageal reflux disease. *Surg Endosc* 2010; **24**: 818-825 [PMID: 19730952 DOI: 10.1007/s00464-009-0671-4]

18 **Arts J**, Bisschops R, Blondeau K, Farré R, Vos R, Holvoet L, Caenepeel P, Lerut A, Tack J. A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD. *Am J Gastroenterol* 2012; **107**: 222-230 [PMID: 22108449 DOI: 10.1038/ajg.2011.395]

19 **Dughera L**, Rotondano G, De Cento M, Cassolino P, Cisarò F. Durability of Stretta Radiofrequency Treatment for GERD: Results of an 8-Year Follow-Up. *Gastroenterol Res Pract* 2014; **2014**: 531907 [PMID: 24959175 DOI: 10.1155/2014/531907]

20 **Tada MSM,** Murakami F, Shimada M, Mizumachi MAT, Yanai H, Oka S, Shigeeda M, Ogino M, Aibe TOY, Takemoto T, Kinoshita Y, Kinoshita K, Iida Y. Development of the strip-off biopsy. *Gastroenterol Endosc* 1984; **26:** 833-839 [DOI: 10.11280/gee1973b.26.833]

21 **Hirao M**, Masuda K, Asanuma T, Naka H, Noda K, Matsuura K, Yamaguchi O, Ueda N. Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. *Gastrointest Endosc* 1988; **34**: 264-269 [PMID: 3391382 DOI: 10.1016/S0016-5107(88)71327-9: ]

22 **Inoue H**, Endo M. Endoscopic esophageal mucosal resection using a transparent tube. *Surg Endosc* 1990; **4**: 198-201 [PMID: 2291159 DOI: 10.1007/BF00316791]

23 **Repici A**, Hassan C, De Paula Pessoa D, Pagano N, Arezzo A, Zullo A, Lorenzetti R, Marmo R. Efficacy and safety of endoscopic submucosal dissection for colorectal neoplasia: a systematic review. *Endoscopy* 2012; **44**: 137-150 [PMID: 22271024 DOI: 10.1055/s-0031-1291448]

24 **Park YM**, Cho E, Kang HY, Kim JM. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. *Surg Endosc* 2011; **25**: 2666-2677 [PMID: 21424201 DOI: 10.1007/s00464-011-1627-z]

25 **Kim JS**, Kim BW, Shin IS. Efficacy and safety of endoscopic submucosal dissection for superficial squamous esophageal neoplasia: a meta-analysis. *Dig Dis Sci* 2014; **59**: 1862-1869 [PMID: 24619279 DOI: 10.1007/s10620-014-3098-2]

26 **Qumseya B**, Panossian AM, Rizk C, Cangemi D, Wolfsen C, Raimondo M, Woodward T, Wallace MB, Wolfsen H. Predictors of esophageal stricture formation post endoscopic mucosal resection. *Clin Endosc* 2014; **47**: 155-161 [PMID: 24765598 DOI: 10.5946/ce.2014.47.2.155]

27 **Sato H**, Inoue H, Kobayashi Y, Maselli R, Santi EG, Hayee B, Igarashi K, Yoshida A, Ikeda H, Onimaru M, Aoyagi Y, Kudo SE. Control of severe strictures after circumferential endoscopic submucosal dissection for esophageal carcinoma: oral steroid therapy with balloon dilation or balloon dilation alone. *Gastrointest Endosc* 2013; **78**: 250-257 [PMID: 23453294 DOI: 10.1016/j.gie.2013.01.008]

28 **Mizuta H**, Nishimori I, Kuratani Y, Higashidani Y, Kohsaki T, Onishi S. Predictive factors for esophageal stenosis after endoscopic submucosal dissection for superficial esophageal cancer. *Dis Esophagus* 2009; **22**: 626-631 [PMID: 19302207 DOI: 10.1111/j.1442-2050.2009.00954.x]

29 **Ohki T**, Yamato M, Ota M, Takagi R, Murakami D, Kondo M, Sasaki R, Namiki H, Okano T, Yamamoto M. Prevention of esophageal stricture after endoscopic submucosal dissection using tissue-engineered cell sheets. *Gastroenterology* 2012; **143**: 582-8.e1-582-8.e2 [PMID: 22561054 DOI: 10.1053/j.gastro.2012.04.050]

30 **Honda M**, Nakamura T, Hori Y, Shionoya Y, Nakada A, Sato T, Yamamoto K, Kobayashi T, Shimada H, Kida N, Hashimoto A, Hashimoto Y. Process of healing of mucosal defects in the esophagus after endoscopic mucosal resection: histological evaluation in a dog model. *Endoscopy* 2010; **42**: 1092-1095 [PMID: 21038294 DOI: 10.1055/s-0030-1255741]

31 **Satodate H**, Inoue H, Yoshida T, Usui S, Iwashita M, Fukami N, Shiokawa A, Kudo SE. Circumferential EMR of carcinoma arising in Barrett's esophagus: case report. *Gastrointest Endosc* 2003; **58**: 288-292 [PMID: 12872107 DOI: 10.1067/mge.2003.361]

32 **Inoue H**, Ito H, Ikeda H, Sato C, Sato H, Phalanusitthepha C, Hayee BH, Eleftheriadis N, Kudo SE. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: a pilot study. *Ann Gastroenterol* 2014; **27**: 346-351 [PMID: 25330784]

33 **Kobara H**, Mori H, Rafiq K, Fujihara S, Nishiyama N, Kato K, Oryu M, Tani J, Miyoshi H, Masaki T. Successful endoscopic treatment of Boerhaave syndrome using an over-the-scope clip. *Endoscopy* 2014; **46** Suppl 1 UCTN: E82-E83 [PMID: 24676827 DOI: 10.1055/s-0032-1326454]

34 **Irani S**, Baron TH, Gluck M, Gan I, Ross AS, Kozarek RA. Preventing migration of fully covered esophageal stents with an over-the-scope clip device (with videos). *Gastrointest Endosc* 2014; **79**: 844-851 [PMID: 24472762 DOI: 10.1016/j.gie.2013.12.012]

35 **Zhang J**, Samarasena JB, Milliken J, Lee JG. Large esophageal fistula closure using an over-the-scope clip: two unique cases. *Ann Thorac Surg* 2013; **96**: 2214-2216 [PMID: 24296187 DOI: 10.1016/j.athoracsur.2013.04.125]

36 **Law R**, Wong Kee Song LM, Irani S, Baron TH. Immediate technical and delayed clinical outcome of fistula closure using an over-the-scope clip device. *Surg Endosc* 2014 [PMID: 25277480 DOI: 10.1007/s00464-014-3860-8]

37 **Pohl J**, Borgulya M, Lorenz D, Ell C. Endoscopic closure of postoperative esophageal leaks with a novel over-the-scope clip system. *Endoscopy* 2010; **42**: 757-759 [PMID: 20806160 DOI: 10.1055/s-0030-1255634]

38 **Seebach L**, Bauerfeind P, Gubler C. "Sparing the surgeon": clinical experience with over-the-scope clips for gastrointestinal perforation. *Endoscopy* 2010; **42**: 1108-1111 [PMID: 21120779 DOI: 10.1055/s-0030-1255924]

39 **Zolotarevsky E**, Kwon Y, Bains M, Schattner M. Esophagobronchial fistula closure using a novel endoscopic over-the-scope-clip. *Ann Thorac Surg* 2012; **94**: e69-e70 [PMID: 22916783 DOI: 10.1016/j.athoracsur.2012.02.025]

40 **Traina M**, Curcio G, Tarantino I, Soresi S, Barresi L, Vitulo P, Gridelli B. New endoscopic over-the-scope clip system for closure of a chronic tracheoesophageal fistula. *Endoscopy* 2010; **42** Suppl 2: E54-E55 [PMID: 20157889 DOI: 10.1055/s-0029-1243824]

41 **von Renteln D**, Denzer UW, Schachschal G, Anders M, Groth S, Rösch T. Endoscopic closure of GI fistulae by using an over-the-scope clip (with videos). *Gastrointest Endosc* 2010; **72**: 1289-1296 [PMID: 20951989 DOI: 10.1016/j.gie.2010.07.033]

42 **Kirschniak A**, Subotova N, Zieker D, Königsrainer A, Kratt T. The Over-The-Scope Clip (OTSC) for the treatment of gastrointestinal bleeding, perforations, and fistulas. *Surg Endosc* 2011; **25**: 2901-2905 [PMID: 21424197 DOI: 10.1007/s00464-011-1640-2]

43 **Kirschniak A**, Kratt T, Stüker D, Braun A, Schurr MO, Königsrainer A. A new endoscopic over-the-scope clip system for treatment of lesions and bleeding in the GI tract: first clinical experiences. *Gastrointest Endosc* 2007; **66**: 162-167 [PMID: 17591492 DOI: 10.1016/j.gie.2007.01.034]

44 **Baron TH**, Song LM, Ross A, Tokar JL, Irani S, Kozarek RA. Use of an over-the-scope clipping device: multicenter retrospective results of the first U.S. experience (with videos). *Gastrointest Endosc* 2012; **76**: 202-208 [PMID: 22726484 DOI: 10.1016/j.gie.2012.03.250]

45 **Conio M**, Blanchi S, Repici A, Bastardini R, Marinari GM. Use of an over-the-scope clip for endoscopic sealing of a gastric fistula after sleeve gastrectomy. *Endoscopy* 2010; **42** Suppl 2: E71-E72 [PMID: 20195971 DOI: 10.1055/s-0029-1215199]

46 **Iacopini F**, Di Lorenzo N, Altorio F, Schurr MO, Scozzarro A. Over-the-scope clip closure of two chronic fistulas after gastric band penetration. *World J Gastroenterol* 2010; **16**: 1665-1669 [PMID: 20355247 DOI: 10.3748/wjg.v16.i13.1665]

47 **Manta R**, Galloro G, Mangiavillano B, Conigliaro R, Pasquale L, Arezzo A, Masci E, Bassotti G, Frazzoni M. Over-the-scope clip (OTSC) represents an effective endoscopic treatment for acute GI bleeding after failure of conventional techniques. *Surg Endosc* 2013; **27**: 3162-3164 [PMID: 23436101 DOI: 10.1007/s00464-013-2871-1]

48 **Nishiyama N**, Mori H, Kobara H, Rafiq K, Fujihara S, Kobayashi M, Oryu M, Masaki T. Efficacy and safety of over-the-scope clip: including complications after endoscopic submucosal dissection. *World J Gastroenterol* 2013; **19**: 2752-2760 [PMID: 23687412 DOI: 10.3748/wjg.v19.i18.2752]

49 **Parodi A**, Repici A, Pedroni A, Blanchi S, Conio M. Endoscopic management of GI perforations with a new over-the-scope clip device (with videos). *Gastrointest Endosc* 2010; **72**: 881-886 [PMID: 20646699 DOI: 10.1016/j.gie.2010.04.006]

50 **Repici A**, Arezzo A, De Caro G, Morino M, Pagano N, Rando G, Romeo F, Del Conte G, Danese S, Malesci A. Clinical experience with a new endoscopic over-the-scope clip system for use in the GI tract. *Dig Liver Dis* 2009; **41**: 406-410 [PMID: 18930700 DOI: 10.1016/j.dld.2008.09.002]

51 **Voermans RP**, Le Moine O, von Renteln D, Ponchon T, Giovannini M, Bruno M, Weusten B, Seewald S, Costamagna G, Deprez P, Fockens P. Efficacy of endoscopic closure of acute perforations of the gastrointestinal tract. *Clin Gastroenterol Hepatol* 2012; **10**: 603-608 [PMID: 22361277 DOI: 10.1016/j.cgh.2012.02.005]

52 **Weiland T**, Fehlker M, Gottwald T, Schurr MO. Performance of the OTSC System in the endoscopic closure of iatrogenic gastrointestinal perforations: a systematic review. *Surg Endosc* 2013; **27**: 2258-2274 [PMID: 23340813 DOI: 10.1007/s00464-012-2754-x]

53 **Mangiavillano B**, Morandi E, Masci E. Accidental endoscopic piercing of the tongue with an Ovesco clip. *Endoscopy* 2012; **44** Suppl 2 UCTN: E221 [PMID: 22622755 DOI: 10.1055/s-0032-1309354]

54 **Coriat R**, Leblanc S, Pommaret E, Berretta O, Prat F, Chaussade S. Endoscopic management of endoscopic submucosal dissection perforations: a new over-the-scope clip device. *Gastrointest Endosc* 2011; **73**: 1067-1069 [PMID: 21521573 DOI: 10.1016/j.gie.2010.10.037]

55 **Sarker S**, Gutierrez JP, Council L, Brazelton JD, Kyanam Kabir Baig KR, Mönkemüller K. Over-the-scope clip-assisted method for resection of full-thickness submucosal lesions of the gastrointestinal tract. *Endoscopy* 2014; **46**: 758-761 [PMID: 24830398 DOI: 10.1055/s-0034-1365513]

56 **Weiland T**, Fehlker M, Gottwald T, Schurr MO. Performance of the OTSC System in the endoscopic closure of gastrointestinal fistulae--a meta-analysis. *Minim Invasive Ther Allied Technol* 2012; **21**: 249-258 [PMID: 22694247 DOI: 10.3109/13645706.2012.694367]

57 **Paspatis GA**, Dumonceau JM, Barthet M, Meisner S, Repici A, Saunders BP, Vezakis A, Gonzalez JM, Turino SY, Tsiamoulos ZP, Fockens P, Hassan C. Diagnosis and management of iatrogenic endoscopic perforations: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. *Endoscopy* 2014; **46**: 693-711 [PMID: 25046348 DOI: 10.1055/s-0034-1377531]

58 **Vaezi MF**, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. *Am J Gastroenterol* 2013; **108**: 1238-149; quiz 1250 [PMID: 23877351 DOI: 10.1038/ajg.2013.196]

59 **Gockel I**, Bohl JR, Eckardt VF, Junginger T. Reduction of interstitial cells of Cajal (ICC) associated with neuronal nitric oxide synthase (n-NOS) in patients with achalasia. *Am J Gastroenterol* 2008; **103**: 856-864 [PMID: 18070236 DOI: 10.1111/j.1572-0241.2007.01667.x]

60 **Boeckxstaens GE**. Achalasia: virus-induced euthanasia of neurons? *Am J Gastroenterol* 2008; **103**: 1610-1612 [PMID: 18557706 DOI: 10.1111/j.1572-0241.2008.01967.x]

61 **Ortega JA**, Madureri V, Perez L. Endoscopic myotomy in the treatment of achalasia. *Gastrointest Endosc* 1980; **26**: 8-10 [PMID: 7358270]

62 **Pasricha PJ**, Hawari R, Ahmed I, Chen J, Cotton PB, Hawes RH, Kalloo AN, Kantsevoy SV, Gostout CJ. Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia. *Endoscopy* 2007; **39**: 761-764 [PMID: 17703382 DOI: 10.1055/s-2007-966764]

63 **Minami H**, Isomoto H, Yamaguchi N, Matsushima K, Akazawa Y, Ohnita K, Takeshima F, Inoue H, Nakao K. Peroral endoscopic myotomy for esophageal achalasia: clinical impact of 28 cases. *Dig Endosc* 2014; **26**: 43-51 [PMID: 23581563 DOI: 10.1111/den.12086]

64 **Von Renteln D**, Fuchs KH, Fockens P, Bauerfeind P, Vassiliou MC, Werner YB, Fried G, Breithaupt W, Heinrich H, Bredenoord AJ, Kersten JF, Verlaan T, Trevisonno M, Rösch T. Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study. *Gastroenterology* 2013; **145**: 309-11.e1-3 [PMID: 23665071 DOI: 10.1053/j.gastro.2013.04.057]

65 **Costamagna G**, Marchese M, Familiari P, Tringali A, Inoue H, Perri V. Peroral endoscopic myotomy (POEM) for oesophageal achalasia: preliminary results in humans. *Dig Liver Dis* 2012; **44**: 827-832 [PMID: 22609465 DOI: 10.1016/j.dld.2012.04.003]

66 **Lee BH**, Shim KY, Hong SJ, Bok GH, Cho JH, Lee TH, Cho JY. Peroral endoscopic myotomy for treatment of achalasia: initial results of a korean study. *Clin Endosc* 2013; **46**: 161-167 [PMID: 23614126 DOI: 10.5946/ce.2013.46.2.161]

67 **Swanstrom LL**, Kurian A, Dunst CM, Sharata A, Bhayani N, Rieder E. Long-term outcomes of an endoscopic myotomy for achalasia: the POEM procedure. *Ann Surg* 2012; **256**: 659-667 [PMID: 22982946 DOI: 10.1097/SLA.0b013e31826b5212]

68 **Friedel D**, Modayil R, Iqbal S, Grendell JH, Stavropoulos SN. Per-oral endoscopic myotomy for achalasia: An American perspective. *World J Gastrointest Endosc* 2013; **5**: 420-427 [PMID: 24044040 DOI: 10.4253/wjge.v5.i9.420]

69 **Swanström LL**, Rieder E, Dunst CM. A stepwise approach and early clinical experience in peroral endoscopic myotomy for the treatment of achalasia and esophageal motility disorders. *J Am Coll Surg* 2011; **213**: 751-756 [PMID: 21996484 DOI: 10.1016/j.jamcollsurg.2011.09.001]

70 **Yoshida A,** Inoue H, Ikeda H, Hosoya T, Onimaru M, Sudo K, Eleftheriadis N, Maselli R, Kudo S. Clinical Results of POEM (Per-Oral Endoscopic Myotomy) for Esophageal Achalasia in 161 Consecutive Cases. *Gastrointest Endosco* 2012; **75** (4S): AB212 [DOI: 10.1016/j.gie.2012.04.379]

71 **Stavropoulos SN,** Modayil R, Brathwaite CE, Halwan B, Ghevariya V, Korrapati V, Dejesus D, Iqbal S, Friedel D, Grendell JH. POEM (PerOral Endoscopic Myotomy): 3 Year Experience by a Gastroenterologist At a US Center. Still Safe and Effective Even in Patients With Advanced Age, Severe Achalasia and Severe Comorbidities. *Gastrointest Endosco* 2013; **77** (5S): AB459 [DOI: 10.1016/j.gie.2013.03.399]

72 **Zhou P**, Yao L, Zhang Y, Cai M, Zhong Y, Ren Z, Xu M, Chen WF, Li QL, Qin XY. PerOral Endoscopic Myotomy (POEM) for Esophageal Achalasia: 205 Cases Report. *Gastrointest Endosco* 2012; **75** (4S): AB132-133 [DOI: 10.1016/j.gie.2012.04.042]

73 **Sharata AM**, Dunst CM, Pescarus R, Shlomovitz E, Wille AJ, Reavis KM, Swanström LL. Peroral Endoscopic Myotomy (POEM) for Esophageal Primary Motility Disorders: Analysis of 100 Consecutive Patients. *J Gastrointest Surg* 2015; **19**: 161-170 [PMID: 25183406 DOI: 10.1007/s11605-014-2610-5]

74 **Stavropoulos SN**, Modayil RJ, Friedel D, Savides T. The International Per Oral Endoscopic Myotomy Survey (IPOEMS): a snapshot of the global POEM experience. *Surg Endosc* 2013; **27**: 3322-3338 [PMID: 23549760 DOI: 10.1007/s00464-013-2913-8]

75 **Boeckxstaens GE**, Annese V, des Varannes SB, Chaussade S, Costantini M, Cuttitta A, Elizalde JI, Fumagalli U, Gaudric M, Rohof WO, Smout AJ, Tack J, Zwinderman AH, Zaninotto G, Busch OR. Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. *N Engl J Med* 2011; **364**: 1807-1816 [PMID: 21561346 DOI: 10.1056/NEJMoa1010502]

76 **Hungness ES**, Teitelbaum EN, Santos BF, Arafat FO, Pandolfino JE, Kahrilas PJ, Soper NJ. Comparison of perioperative outcomes between peroral esophageal myotomy (POEM) and laparoscopic Heller myotomy. *J Gastrointest Surg* 2013; **17**: 228-235 [PMID: 23054897 DOI: 10.1007/s11605-012-2030-3]

77 **Teitelbaum EN**, Rajeswaran S, Zhang R, Sieberg RT, Miller FH, Soper NJ, Hungness ES. Peroral esophageal myotomy (POEM) and laparoscopic Heller myotomy produce a similar short-term anatomic and functional effect. *Surgery* 2013; **154**: 885-91; discussion 891-2 [PMID: 24074428 DOI: 10.1016/j.surg.2013.04.051]

78 **Bhayani NH**, Kurian AA, Dunst CM, Sharata AM, Rieder E, Swanstrom LL. A comparative study on comprehensive, objective outcomes of laparoscopic Heller myotomy with per-oral endoscopic myotomy (POEM) for achalasia. *Ann Surg* 2014; **259**: 1098-1103 [PMID: 24169175 DOI: 10.1097/sla.0000000000000268]

79 **von Renteln D**, Inoue H, Minami H, Werner YB, Pace A, Kersten JF, Much CC, Schachschal G, Mann O, Keller J, Fuchs KH, Rösch T. Peroral endoscopic myotomy for the treatment of achalasia: a prospective single center study. *Am J Gastroenterol* 2012; **107**: 411-417 [PMID: 22068665 DOI: 10.1038/ajg.2011.388]

80 **Inoue H**, Ikeda H, Onimaru M, Yoshida A, Sato H, Santi EG, Maselli R, Eleftheriadis N, Kudo S. Clinical results in 300 cases of POEM for esophageal achalasia: a single institute registered prospective study. *Gastrointest Endosco* 2013; **77** (5s): ab121-122 [DOI: 10.1016/j.gie.2013.04.007]

81 **Onimaru M**, Inoue H, Ikeda H, Yoshida A, Santi EG, Sato H, Ito H, Maselli R, Kudo SE. Peroral endoscopic myotomy is a viable option for failed surgical esophagocardiomyotomy instead of redo surgical Heller myotomy: a single center prospective study. *J Am Coll Surg* 2013; **217**: 598-605 [PMID: 23891071 DOI: 10.1016/j.jamcollsurg.2013.05.025]

82 **Inoue H**, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, Satodate H, Odaka N, Itoh H, Kudo S. Peroral endoscopic myotomy (POEM) for esophageal achalasia. *Endoscopy* 2010; **42**: 265-271 [PMID: 20354937 DOI: 10.1055/s-0029-1244080]

83 **Zhou PH**, Li QL, Yao LQ, Xu MD, Chen WF, Cai MY, Hu JW, Li L, Zhang YQ, Zhong YS, Ma LL, Qin WZ, Cui Z. Peroral endoscopic remyotomy for failed Heller myotomy: a prospective single-center study. *Endoscopy* 2013; **45**: 161-166 [PMID: 23389963 DOI: 10.1055/s-0032-1326203]

84 **Sharata A**, Kurian AA, Dunst CM, Bhayani NH, Reavis KM, Swanström LL. Peroral endoscopic myotomy (POEM) is safe and effective in the setting of prior endoscopic intervention. *J Gastrointest Surg* 2013; **17**: 1188-1192 [PMID: 23609138 DOI: 10.1007/s11605-013-2193-6]

85 **Ren Z**, Zhong Y, Zhou P, Xu M, Cai M, Li L, Shi Q, Yao L. Perioperative management and treatment for complications during and after peroral endoscopic myotomy (POEM) for esophageal achalasia (EA) (data from 119 cases). *Surg Endosc* 2012; **26**: 3267-3272 [PMID: 22609984 DOI: 10.1007/s00464-012-2336-y]

86 **Kandulski A**, Fuchs KH, Weigt J, Malfertheiner P. Jackhammer esophagus: high-resolution manometry and therapeutic approach using peroral endoscopic myotomy (POEM). *Dis Esophagus* 2014 [PMID: 24460870 DOI: 10.1111/dote.12182]

87 **Khashab MA**, Saxena P, Kumbhari V, Nandwani M, Roland BC, Stein E, Clarke JO, Stavropoulos S, Inoue H, Pasricha PJ. Peroral endoscopic myotomy as a platform for the treatment of spastic esophageal disorders refractory to medical therapy (with video). *Gastrointest Endosc* 2014; **79**: 136-139 [PMID: 24342590 DOI: 10.1016/j.gie.2013.08.021]

88 **Li QL**, Chen WF, Zhou PH, Yao LQ, Xu MD, Hu JW, Cai MY, Zhang YQ, Qin WZ, Ren Z. Peroral endoscopic myotomy for the treatment of achalasia: a clinical comparative study of endoscopic full-thickness and circular muscle myotomy. *J Am Coll Surg* 2013; **217**: 442-451 [PMID: 23891074 DOI: 10.1016/j.jamcollsurg.2013.04.033]

89 **Hedenbro JL**, Ekelund M, Wetterberg P. Endoscopic diagnosis of submucosal gastric lesions. The results after routine endoscopy. *Surg Endosc* 1991; **5**: 20-23 [PMID: 1871670]

90 **Miettinen M**, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. *Pol J Pathol* 2003; **54**: 3-24 [PMID: 12817876]

91 **Winant AJ**, Gollub MJ, Shia J, Antonescu C, Bains MS, Levine MS. Imaging and clinicopathologic features of esophageal gastrointestinal stromal tumors. *AJR Am J Roentgenol* 2014; **203**: 306-314 [PMID: 25055264 DOI: 10.2214/ajr.13.11841]

92 **Mutrie CJ**, Donahue DM, Wain JC, Wright CD, Gaissert HA, Grillo HC, Mathisen DJ, Allan JS. Esophageal leiomyoma: a 40-year experience. *Ann Thorac Surg* 2005; **79**: 1122-1125 [PMID: 15797036 DOI: 10.1016/j.athoracsur.2004.08.029]

93 **Punpale A**, Rangole A, Bhambhani N, Karimundackal G, Desai N, de Souza A, Pramesh CS, Jambhekar N, Mistry RC. Leiomyoma of esophagus. *Ann Thorac Cardiovasc Surg* 2007; **13**: 78-81 [PMID: 17505413]

94 **Robb WB**, Bruyere E, Amielh D, Vinatier E, Mabrut JY, Perniceni T, Piessen G, Mariette C. Esophageal gastrointestinal stromal tumor: is tumoral enucleation a viable therapeutic option? *Ann Surg* 2015; **261**: 117-124 [PMID: 25062398 DOI: 10.1097/sla.0000000000000505]

95 **Jiang G**, Zhao H, Yang F, Li J, Li Y, Liu Y, Liu J, Wang J. Thoracoscopic enucleation of esophageal leiomyoma: a retrospective study on 40 cases. *Dis Esophagus* 2009; **22**: 279-283 [PMID: 19021682 DOI: 10.1111/j.1442-2050.2008.00883.x]

96 **Shin S**, Choi YS, Shim YM, Kim HK, Kim K, Kim J. Enucleation of esophageal submucosal tumors: a single institution's experience. *Ann Thorac Surg* 2014; **97**: 454-459 [PMID: 24360088 DOI: 10.1016/j.athoracsur.2013.10.030]

97 **Inoue H**, Ikeda H, Hosoya T, Onimaru M, Yoshida A, Eleftheriadis N, Maselli R, Kudo S. Submucosal endoscopic tumor resection for subepithelial tumors in the esophagus and cardia. *Endoscopy* 2012; **44**: 225-230 [PMID: 22354822 DOI: 10.1055/s-0031-1291659]

98 **Wang XY**, Xu MD, Yao LQ, Zhou PH, Pleskow D, Li QL, Zhang YQ, Chen WF, Zhong YS. Submucosal tunneling endoscopic resection for submucosal tumors of the esophagogastric junction originating from the muscularis propria layer: a feasibility study (with videos). *Surg Endosc* 2014; **28**: 1971-1977 [PMID: 24515260 DOI: 10.1007/s00464-014-3420-2]

99 **Wang L**, Ren W, Zhang Z, Yu J, Li Y, Song Y. Retrospective study of endoscopic submucosal tunnel dissection (ESTD) for surgical resection of esophageal leiomyoma. *Surg Endosc* 2013; **27**: 4259-4266 [PMID: 23955726 DOI: 10.1007/s00464-013-3035-z]

100 **Kumbhari V**, Saxena P, Azola A, Messallam AA, El Zein MH, Khashab MA. Submucosal tunneling endoscopic resection of a giant esophageal leiomyoma. *Gastrointest Endosc* 2015; **81**: 219-220 [PMID: 24916926 DOI: 10.1016/j.gie.2014.04.010]

101 **Saxena P**, Chavez YH, Kord Valeshabad A, Kalloo AN, Khashab MA. An alternative method for mucosal flap closure during peroral endoscopic myotomy using an over-the-scope clipping device. *Endoscopy* 2013; **45**: 579-581 [PMID: 23592391 DOI: 10.1055/s-0032-1326398]

102 **Yang D**, Draganov PV. Closing the gap in POEM. *Endoscopy* 2013; **45**: 677 [PMID: 23881808 DOI: 10.1055/s-0033-1344147]

103 **Liu BR**, Song JT, Kong LJ, Pei FH, Wang XH, Du YJ. Tunneling endoscopic muscularis dissection for subepithelial tumors originating from the muscularis propria of the esophagus and gastric cardia. *Surg Endosc* 2013; **27**: 4354-4359 [PMID: 23765425 DOI: 10.1007/s00464-013-3023-3]

104 **Ye LP**, Zhang Y, Mao XL, Zhu LH, Zhou X, Chen JY. Submucosal tunneling endoscopic resection for small upper gastrointestinal subepithelial tumors originating from the muscularis propria layer. *Surg Endosc* 2014; **28**: 524-530 [PMID: 24013472 DOI: 10.1007/s00464-013-3197-8]

105 **Cai M**, Chen J, Zhou P, Yao L. The rise of tunnel endoscopic surgery: a case report and literature review. *Case Rep Gastrointest Med* 2012; **2012**: 847640 [PMID: 22988531 DOI: 10.1155/2012/847640]

106 **Gong W**, Xiong Y, Zhi F, Liu S, Wang A, Jiang B. Preliminary experience of endoscopic submucosal tunnel dissection for upper gastrointestinal submucosal tumors. *Endoscopy* 2012; **44**: 231-235 [PMID: 22354823 DOI: 10.1055/s-0031-1291720]

107 **Xu MD**, Cai MY, Zhou PH, Qin XY, Zhong YS, Chen WF, Hu JW, Zhang YQ, Ma LL, Qin WZ, Yao LQ. Submucosal tunneling endoscopic resection: a new technique for treating upper GI submucosal tumors originating from the muscularis propria layer (with videos). *Gastrointest Endosc* 2012; **75**: 195-199 [PMID: 22056087 DOI: 10.1016/j.gie.2011.08.018]

108 **Xu MD**, Lu W, Li QL, Zhou PH, Zhong YS, Chen WF, Zhang YQ, Yao LQ. [Application and evaluation of submucosal tunneling endoscopic resection of gastric submucosal tumors originating from the muscularis propria layer]. *Zhonghua Wei Chang Wai Ke Za Zhi* 2012; **15**: 671-674 [PMID: 22851066]

109 **Chen H**, Xu Z, Huo J, Liu D. Submucosal tunneling endoscopic resection for simultaneous esophageal and cardia submucosal tumors originating from the muscularis propria layer (with video). *Dig Endosc* 2015; **27**: 155-158 [PMID: 24444087 DOI: 10.1111/den.12227]

110 **Lu J**, Jiao T, Zheng M, Lu X. Endoscopic resection of submucosal tumors in muscularis propria: the choice between direct excavation and tunneling resection. *Surg Endosc* 2014; **28**: 3401-3407 [PMID: 24986008 DOI: 10.1007/s00464-014-3610-y]

111 **Lu J**, Zheng M, Jiao T, Wang Y, Lu X. Transcardiac tunneling technique for endoscopic submucosal dissection of gastric fundus tumors arising from the muscularis propria. *Endoscopy* 2014; **46**: 888-892 [PMID: 25036658 DOI: 10.1055/s-0034-1377442]

112 **Celestin LR**. Permanent intubation in inoperable cancer of the oesophagus and cardia: a new tube. *Ann R Coll Surg Engl* 1959; **25**: 165-170 [PMID: 13808746]

113 **Atkinson M**, Ferguson R. Fibreoptic endoscopic palliative intubation of inoperable oesophagogastric neoplasms. *Br Med J* 1977; **1**: 266-267 [PMID: 65197]

114 **Knyrim K**, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. *N Engl J Med* 1993; **329**: 1302-1307 [PMID: 7692297 DOI: 10.1056/nejm199310283291803]

115 **van Heel NC**, Haringsma J, Boot H, Cats A, Vanhoutvin SA, Kuipers EJ. Comparison of 2 expandable stents for malignant esophageal disease: a randomized controlled trial. *Gastrointest Endosc* 2012; **76**: 52-58 [PMID: 22726466 DOI: 10.1016/j.gie.2012.02.050]

116 **Sandha GS**, Marcon NE. Expandable metal stents for benign esophageal obstruction. *Gastrointest Endosc Clin N Am* 1999; **9**: 437-446 [PMID: 10388859]

117 **Hramiec JE**, O'Shea MA, Quinlan RM. Expandable metallic esophageal stents in benign disease: a cause for concern. *Surg Laparosc Endosc* 1998; **8**: 40-43 [PMID: 9488569]

118 **Ackroyd R**, Watson DI, Devitt PG, Jamieson GG. Expandable metallic stents should not be used in the treatment of benign esophageal strictures. *J Gastroenterol Hepatol* 2001; **16**: 484-487 [PMID: 11354292 DOI: 10.1046/j.1440-1746.2001.02367.x]

119 **Martins BC**, Retes FA, Medrado BF, de Lima MS, Pennacchi CM, Kawaguti FS, Safatle-Ribeiro AV, Uemura RS, Maluf-Filho F. Endoscopic management and prevention of migrated esophageal stents. *World J Gastrointest Endosc* 2014; **6**: 49-54 [PMID: 24567792 DOI: 10.4253/wjge.v6.i2.49]

120 **Vanbiervliet G**, Filippi J, Karimdjee BS, Venissac N, Iannelli A, Rahili A, Benizri E, Pop D, Staccini P, Tran A, Schneider S, Mouroux J, Gugenheim J, Benchimol D, Hébuterne X. The role of clips in preventing migration of fully covered metallic esophageal stents: a pilot comparative study. *Surg Endosc* 2012; **26**: 53-59 [PMID: 21792721 DOI: 10.1007/s00464-011-1827-6]

121 **Fujii LL**, Bonin EA, Baron TH, Gostout CJ, Wong Kee Song LM. Utility of an endoscopic suturing system for prevention of covered luminal stent migration in the upper GI tract. *Gastrointest Endosc* 2013; **78**: 787-793 [PMID: 23871095 DOI: 10.1016/j.gie.2013.06.014]

122 **Mudumbi S**, Velazquez-Aviña J, Neumann H, Kyanam Kabir Baig KR, Mönkemüller K. Anchoring of self-expanding metal stents using the over-the-scope clip, and a technique for subsequent removal. *Endoscopy* 2014; **46**: 1106-1109 [PMID: 25268306 DOI: 10.1055/s-0034-1377916]

123 **Dasari BV**, Neely D, Kennedy A, Spence G, Rice P, Mackle E, Epanomeritakis E. The role of esophageal stents in the management of esophageal anastomotic leaks and benign esophageal perforations. *Ann Surg* 2014; **259**: 852-860 [PMID: 24509201 DOI: 10.1097/sla.0000000000000564]

124 **Thomas T**, Abrams KR, Subramanian V, Mannath J, Ragunath K. Esophageal stents for benign refractory strictures: a meta-analysis. *Endoscopy* 2011; **43**: 386-393 [PMID: 21437850 DOI: 10.1055/s-0030-1256331]

125 **Repici A**, Hassan C, Sharma P, Conio M, Siersema P. Systematic review: the role of self-expanding plastic stents for benign oesophageal strictures. *Aliment Pharmacol Ther* 2010; **31**: 1268-1275 [PMID: 20236257 DOI: 10.1111/j.1365-2036.2010.04301.x]

126 **Ham YH**, Kim GH. Plastic and biodegradable stents for complex and refractory benign esophageal strictures. *Clin Endosc* 2014; **47**: 295-300 [PMID: 25133114 DOI: 10.5946/ce.2014.47.4.295]

127 **Foschia F**, De Angelis P, Torroni F, Romeo E, Caldaro T, di Abriola GF, Pane A, Fiorenza MS, De Peppo F, Dall'Oglio L. Custom dynamic stent for esophageal strictures in children. *J Pediatr Surg* 2011; **46**: 848-853 [PMID: 21616239 DOI: 10.1016/j.jpedsurg.2011.02.014]

128 **De Peppo F**, Zaccara A, Dall'Oglio L, Federici di Abriola G, Ponticelli A, Marchetti P, Lucchetti MC, Rivosecchi M. Stenting for caustic strictures: esophageal replacement replaced. *J Pediatr Surg* 1998; **33**: 54-57 [PMID: 9473100 DOI: 10.1016/S0022-3468(98)90361-X]

129 **Eloubeidi MA**, Talreja JP, Lopes TL, Al-Awabdy BS, Shami VM, Kahaleh M. Success and complications associated with placement of fully covered removable self-expandable metal stents for benign esophageal diseases (with videos). *Gastrointest Endosc* 2011; **73**: 673-681 [PMID: 21272871 DOI: 10.1016/j.gie.2010.11.014]

130 **van Boeckel PG**, Dua KS, Weusten BL, Schmits RJ, Surapaneni N, Timmer R, Vleggaar FP, Siersema PD. Fully covered self-expandable metal stents (SEMS), partially covered SEMS and self-expandable plastic stents for the treatment of benign esophageal ruptures and anastomotic leaks. *BMC Gastroenterol* 2012; **12**: 19 [PMID: 22375711 DOI: 10.1186/1471-230x-12-19]

131 **Bakken JC**, Wong Kee Song LM, de Groen PC, Baron TH. Use of a fully covered self-expandable metal stent for the treatment of benign esophageal diseases. *Gastrointest Endosc* 2010; **72**: 712-720 [PMID: 20883848 DOI: 10.1016/j.gie.2010.06.028]

132 **Schweigert M**, Dubecz A, Stadlhuber RJ, Muschweck H, Stein HJ. Risk of stent-related aortic erosion after endoscopic stent insertion for intrathoracic anastomotic leaks after esophagectomy. *Ann Thorac Surg* 2011; **92**: 513-518 [PMID: 21592460 DOI: 10.1016/j.athoracsur.2011.02.083]


133 **Rogart J**, Greenwald A, Rossi F, Barrett P, Aslanian H. Aortoesophageal fistula following Polyflex stent placement for refractory benign esophageal stricture. *Endoscopy* 2007; **39** Suppl 1: E321-E322 [PMID: 18273774 DOI: 10.1055/s-2007-966803]

134 **van Geenen EJ**, Visser NC, Bonenkamp JJ. Fatal aortogastric fistula following fully covered metal stent placement for refractory esophageal stricture. *Endoscopy* 2014; **46** Suppl 1 UCTN: E16-E17 [PMID: 24523161 DOI: 10.1055/s-0033-1344561]

135 **Hirdes MM**, Siersema PD, van Boeckel PG, Vleggaar FP. Single and sequential biodegradable stent placement for refractory benign esophageal strictures: a prospective follow-up study. *Endoscopy* 2012; **44**: 649-654 [PMID: 22723182 DOI: 10.1055/s-0032-1309818]

136 **Repici A**, Vleggaar FP, Hassan C, van Boeckel PG, Romeo F, Pagano N, Malesci A, Siersema PD. Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. *Gastrointest Endosc* 2010; **72**: 927-934 [PMID: 21034894 DOI: 10.1016/j.gie.2010.07.031]


**P-Reviewer:** Aly EH, Chung JW, Kamberoglou D, Stephenne X, Syam AF **S-Editor:** Ji FF **L-Editor: E-Editor:**




**Figure 1 Completed antireflux mucosectomy.** A: View on expiration; B: View on inspiration.

**


**Figure 2 The over the scope clip device.** Left: Clip mounted onto the distal tip of an endoscope with Twin Grasper projecting from the working channel; Right: The different over the scope clip tooth configurations available. (With permission from OVESCO Endoscopy, Germany).



**Figure 3 Steps in Per-oral endoscopic myotomy.** A: Submucosal injection; B: Mucosal incision; C: Submucosal tunneling; D: Completed Tunnel; E: Circular muscle myotomy; F: Closer of mucosal incision.



**Figure 4 Per oral endoscopic tumor of Leiomyoma.** A: Subepithelial tumor (SET) (black arrow) and incidental papilloma (red arrow); B: Mucosal incision with TT knife; C: Creation of submucosal tunnel; D: First encounter with SET in tunnel; E: Dissection of tumor; F: Dissected SET; G: Completed full thickness resection; H: Closure of incision; I: Extracted SET with intact capsule.



**Figure 5 Examples of fully covered self-expandable metal stents, self-expandable plastic stents and biodegradable stents.** Left: Biodegradable stent (ELLA-CS, Czech Republic) composed of polypdiaxanone monofilament; Middle: Fully covered Evolution® stent composed of nitinol silicone coating (Cook, United States); Right: Fully covered silicon constructed Polyflex® stent (Boston Scientific, United States).

**Table 1 Series reporting Eckardt post Per-oral endoscopic myotomy for achalasia**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Ref. | Country | No. of patients | Success rate (%) | Complications  (%) | Mean follow-up (mo) |
| Inoue *et al*[82]2010a | Japan | 17 | 100 | 0 | 5 |
| Von Renteln *et al*[79] 2012 | Germany | 16 | 94 | 12.5 | 3 |
| Swanström *et al*[67] 2012 | United States | 18 | 100 | 16.7 | 11 |
| Ren *et al*[85] 2012 | China | 119 | 94 | 55 | 3 |
| Costamagna *et al*[65] 2012 | Italy | 11 | 100 | 0 | 3 |
| Lee *et al*[66] 2013 | South Korea | 13 | 100 | 0 | 7 |
| Hungness *et al*[76] 2013 | United States | 18 | 89 | 22 | 6 |
| Teitelbaum *et al*[77] 2013 | United States | 12 | 100 | NR | 9 |
| Zhou *et al*[83] 2013b | China | 12 | 92 | 16.7 | 10 |
| Von Renteln *et al*[64] 2013c | International | 70 | 82.4 | 14.3 | 12 |
| Sharata *et al*[84] 2013**d** | United States | 31 | 100 | 12.5 | 6 |
| Freidel *et al*[68] 2013 | United States | 45 | 95 | 33 | 3 |
| Inoue *et al*[80] 2013 | Japan | 300 | 100 | 6 | 12 |
| Sharata *et al*[73] 2014 | United States | 75 | 98 | 11 | 16 |
| Bhayani *et al*[78] 2014 | United States | 37 | 100 | 13.5 | 6 |
| Minami *et al*[63] 2014 | Japan | 28 | 96 | 0 | 3 |

aEckard score was not used, but rather a dysphagia symptoms score which decreased from mean of 10 to 1.3; bAll patient had previous laparoscopic Heller myotomy; cEuropean and North American; dIncluded other spastic esophageal disorders, total 31 achalasia cases; Complications rate reported is for all 40 cases performed. NR: Not reported.

**Table 2 Series reporting on safety and efficacy of Per oral endoscopic tumor**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ref. | Country | No. of patients | Mean Tumor Size  (mm) | Complete resectionb  (%) | Piecemeal or disrupted capsule  (%) | Complications  (%) |
| Inoue *et al*[97]2011a | Japan | 9 | 29.4 | 100 (7/9) | 0 | 0 |
| Cai *et al*[105] 2012 | China | 1 | 20 | 100 | NS | 100 |
| Gong *et al*[106] 2012 | China | 12 | 19.5 | 83.3 (10/12) | 16.7 (2/12) | 16.7 |
| Xu *et al*[107] 2012 | China | 15 | 19.0 | 100 | 0 | 13.3 |
| Liu *et al*[103] 2013 | China | 12 | 18.5 | 100 | 0 | 66.7 |
| Xu *et al*[108] 2013 | China | 23 | 21 | 100 | 0 | 39 |
| Wang *et al*[99] 2013 | China | 18 | 33 | NS | NS | 16.7 |
| Chen *et al*[109] 2014 | China | 1 | #1 = 25  #2 = 30 | 100 | 0 | 0 |
| Kumbhari *et al*[100] 2014 | United States | 1 | 60 | 0 | 100 | NS |
| Lu *et al*[110] 2014 | China | 42 | 12.1 | 97.7 (44/45) | 2.3 (1/45) | 15.6 |
| Ye *et al*[104] 2014 | China | 85 | 19.2 | 100 | 0 | 9.4 |
| Wang *et al*[98] 2014 | China | 57 | 21.5 | 100 | 0 | 21 |
| Lu *et al*[111] 2014c | China | 18 | 21 | 100 | 0 | 11.1 |

aThe 2 subepithelial tumors (SETs) that could not be resected were 60 mm and 75 mm in size and an adequate endoscopic field for safe extraction was not possible; bComplete resection refers to *en bloc* extraction of the tumor with intact capsule and clear margins; cSeries included only cardia and gastric SETs. NS: Not specified.

Table 3 General differences between stents for benign esophageal disease

|  |  |  |
| --- | --- | --- |
| Stent type | Advantages | Disadvantages |
| FCSEMS | No requirement for pre-dilation  Recapture is possible | Expensive  High migration risk  Increased tissue hyperplasia |
| SEPS | Cheaper than other covered stents  Decreased tissue hyperplasia | High migration risk (potentially more than FCSEMS)  Require manual loading  Require pre-dilation |
| BDS | No need to remove  Less migration risk | Expensive  Increased risk of post-procedure pain  Require manual loading  Require pre-dilation |

FCSEMS: Fully covered self-expandable metal stents; SEPS: Self-expandable plastic stents; BDS: Biodegradable stents.